Drug Profile
Research programme: gastrointestinal disorders - Ajinomoto Pharmaceuticals/RaQualia Pharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ajinomoto Pharma; RaQualia Pharma
- Class
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan
- 31 Oct 2012 Early research in Gastrointestinal disorders in Japan (unspecified route)